Interferon alfa-2b in the treatment of chronic myelogenous leukaemia

Masami Bessho , Nobutaka Kawai , Kunitake Hirashima
{"title":"Interferon alfa-2b in the treatment of chronic myelogenous leukaemia","authors":"Masami Bessho ,&nbsp;Nobutaka Kawai ,&nbsp;Kunitake Hirashima","doi":"10.1016/0277-5379(91)90560-Z","DOIUrl":null,"url":null,"abstract":"<div><p>Recent reports have indicated that alpha interferon can be an effective treatment for patients with chronic myelogenous leukaemia (CML) [1]. In order to evaluate the clinical usefulness of interferon alfa-2b, we treated six patients with chronic phase CML and observed their clinical course.</p><p>The patients consisted of four males and two females, aged between 39 and 58 years, who had previously received either treatment with busulfan (four patients) or no therapy (two patients). Interferon alfa-2b was administered intramuscularly at a dose of 3–10 million units (MU)/body, either daily or three times per week, for more than 8 weeks.</p><p>All six patients showed a fall in white blood cell count from a mean of 101.8 × 10<sup>9</sup>/L (range 15.6–330) before treatment to a mean of 25.7 × 10<sup>9</sup>/L (range 4.0–117) after treatment with interferon alfa-2b. Haemoglobin remained largely unchanged, and platelet counts fluctuated. Two of the six patients also showed a slight reduction in the percentage of Ph<sup>1</sup>-positive clones (to 98% and 96%, respectively).</p><p>Complete haematological response was achieved in four patients, partial haematological response in one and no response in one. All six patients are alive at a mean of 69 months (range 38–108 months) from diagnosis and are either in chronic phase (five patients) or post bone marrow transplant (one patient).</p><p>Major side effects of alpha interferon included fever, general fatigue, and nausea, but all were tolerable.</p><p>In conclusion, alpha interferon was useful for controlling blood cell counts in chronic phase CML patients, with tolerable side effects. Five of six patients achieved long-term haematological remission, and alpha interferon slightly reduced the fraction of Ph<sup>1</sup>-positive clones in two patients.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90560-Z","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190560Z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Recent reports have indicated that alpha interferon can be an effective treatment for patients with chronic myelogenous leukaemia (CML) [1]. In order to evaluate the clinical usefulness of interferon alfa-2b, we treated six patients with chronic phase CML and observed their clinical course.

The patients consisted of four males and two females, aged between 39 and 58 years, who had previously received either treatment with busulfan (four patients) or no therapy (two patients). Interferon alfa-2b was administered intramuscularly at a dose of 3–10 million units (MU)/body, either daily or three times per week, for more than 8 weeks.

All six patients showed a fall in white blood cell count from a mean of 101.8 × 109/L (range 15.6–330) before treatment to a mean of 25.7 × 109/L (range 4.0–117) after treatment with interferon alfa-2b. Haemoglobin remained largely unchanged, and platelet counts fluctuated. Two of the six patients also showed a slight reduction in the percentage of Ph1-positive clones (to 98% and 96%, respectively).

Complete haematological response was achieved in four patients, partial haematological response in one and no response in one. All six patients are alive at a mean of 69 months (range 38–108 months) from diagnosis and are either in chronic phase (five patients) or post bone marrow transplant (one patient).

Major side effects of alpha interferon included fever, general fatigue, and nausea, but all were tolerable.

In conclusion, alpha interferon was useful for controlling blood cell counts in chronic phase CML patients, with tolerable side effects. Five of six patients achieved long-term haematological remission, and alpha interferon slightly reduced the fraction of Ph1-positive clones in two patients.

干扰素α -2b治疗慢性髓性白血病的研究
最近的报道表明,α干扰素可以有效治疗慢性髓性白血病(CML)患者[1]。为了评价干扰素α -2b的临床应用价值,我们对6例慢性粒细胞白血病(CML)患者进行治疗并观察其临床病程。患者包括4名男性和2名女性,年龄在39至58岁之间,先前接受过布苏凡治疗(4例)或未接受治疗(2例)。干扰素α -2b肌注剂量为300 - 1000万单位(MU)/体,每日或每周3次,疗程超过8周。所有6例患者的白细胞计数均从治疗前的平均101.8 × 109/L(范围15.6-330)下降到干扰素α -2b治疗后的平均25.7 × 109/L(范围4.0-117)。血红蛋白基本保持不变,血小板计数波动。6名患者中的2名也显示出ph1阳性克隆的百分比略有下降(分别为98%和96%)。4例患者达到完全血液学反应,1例达到部分血液学反应,1例无反应。所有6例患者从诊断起平均存活69个月(38-108个月),处于慢性期(5例)或骨髓移植后(1例)。干扰素的主要副作用包括发热、全身乏力和恶心,但都是可以忍受的。总之,α干扰素可用于控制慢性期CML患者的血细胞计数,副作用可耐受。6名患者中有5名实现了长期血液学缓解,α干扰素在2名患者中略微降低了ph1阳性克隆的比例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信